Successful expansion and cryopreservation of human natural killer cell line NK-92 for clinical manufacturing
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0294857 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Seul Lee und 15 weiteren Autor:innen. Beteiligte Einrichtung: Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Dimethyl Sulfoxide, Cryopreservation. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Natural killer (NK) cells have recently shown renewed promise as therapeutic cells for use in treating hematologic cancer indications. Despite this promise, NK cell manufacturing workflows remain largely manual, open, and disconnected, and depend on feeders, as well as outdated unit operations or processes, often utilizing research-grade reagents. Successful scale-up of NK cells critically depends on the availability and performance of nutrient-rich expansion media and cryopreservation conditions that are conducive to high cell viability and recovery post-thaw. In this paper we used Cytiva hardware and media to expand the NK92 cell line in a model process that is suitable for GMP and clinical manufacturing of NK cells. We tested a range of cryopreservation factors including cooling rate, a range of DMSO-containing and DMSO-free cryoprotectants, ice nucleation, and cell density. Higher post-thaw recovery was seen in cryobags over cryovials cooled in identical conditions, and cooling rates of 1°C/min or 2°C/min optimal for cryopreservation in DMSO-containing and DMSO-free cryoprotectants respectively. Higher cell densities of 5x10 7 cells/ml gave higher post-thaw viability than those cryopreserved at either 1x10 6 or 5x10 6 cells/ml. This enabled us to automate, close and connect unit operations within the workflow while demonstrating superior expansion and cryopreservation of NK92 cells. Cellular outputs and performance were conducive to clinical dosing regimens, serving as a proof-of-concept for future clinical and commercial manufacturing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea.
- Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea.
- Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
- Global Life Sciences Solutions, Cambridge, United Kingdom.
- Global Life Sciences Solutions USA LLC 100 Results Way, Marlborough, MA, United States of America.
- Global Life Sciences Solutions Singapore Pte. Ltd., HarbourFront Center, Singapore, Singapore.
ORCID-Profile: Seul Lee, Peter Kilbride, Byoung Chul Cho
Förderung
- National Research Foundation of Korea
Zitieren
APA
Lee, S., Joo, Y., Lee, E. J., Byeon, Y., Kim, J. H., Pyo, K. H., Kim, Y. S., Lim, S. M., Kilbride, P., Iyer, R. K., Li, M., French, M. C., Lee, J. Y., Kang, J., Byun, H., & Cho, B. C. (2024). Successful expansion and cryopreservation of human natural killer cell line NK-92 for clinical manufacturing. PLOS ONE. https://doi.org/10.1371/journal.pone.0294857
Vancouver
Lee S, Joo Y, Lee EJ, Byeon Y, Kim JH, Pyo KH, et al. Successful expansion and cryopreservation of human natural killer cell line NK-92 for clinical manufacturing. PLOS ONE. 2024. doi:10.1371/journal.pone.0294857
BibTeX
@article{Lee2024,
author = {Lee, Seul and Joo, Yunjoo and Lee, Eun Ji and Byeon, Youngseon and Kim, Jae-Hwan and Pyo, Kyoung-Ho and Kim, Young Seob and Lim, Sun Min and Kilbride, Peter and Iyer, Rohin K and Li, Mingming and French, Mandy C and Lee, Jung-Yub and Kang, Jeeheon and Byun, Hyesin and Cho, Byoung Chul},
title = {Successful expansion and cryopreservation of human natural killer cell line NK-92 for clinical manufacturing},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0294857}
}
EUVIMED